Ga-68 Prostate Specific Membrane Antigen PET/CT in Gliomas

Launched by ALL INDIA INSTITUTE OF MEDICAL SCIENCES, BHUBANESWAR · Feb 1, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique called Ga-68 Prostate Specific Membrane Antigen (PSMA) PET/CT to see how well it can detect recurrent gliomas, which are types of brain tumors. Researchers want to find out if this method provides more accurate results compared to the standard imaging tests currently used. Gliomas include various forms of brain tumors such as astrocytomas and glioblastomas, and the trial is focused on improving the way these tumors are diagnosed, especially when they come back after treatment.

To participate in this trial, you need to be at least 18 years old and have a confirmed history of glioma, having previously undergone treatment like surgery, radiation, or chemotherapy. Additionally, participants should have a suspicion of tumor recurrence and be able to give their consent to join the study. However, individuals who are pregnant, breastfeeding, or have other serious health issues are not eligible. If you join the trial, you can expect to undergo the Ga-68 PSMA PET/CT scan, which is a specialized imaging test that helps doctors see if the tumor has returned. Overall, this trial aims to enhance the way gliomas are monitored and treated, potentially leading to better care for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with age more than18 years.
• • Patients having past history of histologically proven glioma.
• • Patients who have undergone prior treatment with tumor resection and/or radiation therapy and/or chemotherapy.
• • Clinically suspected cases of recurrence.
• • Patient should be willing to and able to give written informed consent
• Exclusion Criteria:
• • Pregnant lady.
• • Breastfeeding mother.
• • Patients who will deny to give consent.
• • Any brain primary other than high grade glioma
• • Patient diagnosed with other primary malignancy
• • Patient with life threating neurological emergency